Pashirzad, Mehran and Khorasanian, Reihaneh and Fard, Maryam Mahmoudi and Arjmand, Mohammad-Hassan and Langari, Hadis and Khazaei, Majid and Soleimanpour, Saman and Rezayi, Majid and Ferns, Gordon A. and Hassanian, Seyed Mahdi and Avan, Amir (2021) The Therapeutic Potential of MAPK/ERK Inhibitors in the Treatment of Colorectal Cancer. CURRENT CANCER DRUG TARGETS, 21 (11). pp. 932-943.
Full text not available from this repository.Abstract
The MAPK/ERK signaling pathway regulates cancer cell proliferation, apoptosis, inflammation, angiogenesis, metastasis and drug resistance. Mutations and up-regulation of components of the MAPK/ERK signaling pathway, as well as over-activation of this critical signaling pathway, are frequently observed in colorectal carcinomas. Targeting the MAPK/ERK signaling pathway, using specific pharmacological inhibitors, elicits potent anti-tumor effects, supporting the therapeutic potential of these inhibitors in the treatment of CRC. Several drugs have recently been developed for the inhibition of the MEK/ERK pathway in preclinical and clinical settings, such as MEK162 and MK-2206. MEK1/2 inhibitors demonstrate promising efficacy and anticancer activity for the treatment of this malignancy. This review summarizes the current knowledge on the role of the MAPK/ERK signaling pathway in the pathogenesis of CRC and the potential clinical value of synthetic inhibitors of this pathway in preventing CRC progression for a better understanding, and hence, better management of colorectal cancer.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MAPK signaling pathway; ERK signaling pathway; ERK inhibitors; MEK1; 2 inhibitors; tumor progression |
| Subjects: | WI Digestive System QU Biochemistry QZ pathology-Neoplasms |
| Divisions: | Reserach Vice-Chancellar Department > Medical Plants Research Center |
| Depositing User: | zeynab . bagheri |
| Date Deposited: | 09 Feb 2022 06:10 |
| Last Modified: | 09 Feb 2022 06:10 |
| URI: | http://eprints.skums.ac.ir/id/eprint/9297 |
Actions (login required)
 |
View Item |
